(NASDAQ: BEAM) Beam Therapeutics's forecast annual revenue growth rate of 2.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 103.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Beam Therapeutics's revenue in 2025 is $55,701,000.On average, 18 Wall Street analysts forecast BEAM's revenue for 2025 to be $3,853,510,998, with the lowest BEAM revenue forecast at $1,591,127,122, and the highest BEAM revenue forecast at $5,391,363,775. On average, 18 Wall Street analysts forecast BEAM's revenue for 2026 to be $4,875,465,159, with the lowest BEAM revenue forecast at $2,983,363,354, and the highest BEAM revenue forecast at $11,720,356,032.
In 2027, BEAM is forecast to generate $6,241,622,330 in revenue, with the lowest revenue forecast at $2,983,363,354 and the highest revenue forecast at $12,785,842,944.